John DeFlice, MD

John DeFlice is a nine year survivor of multiple myeloma. He had a stem cell transplant in 2011 and is currently on maintenance therapy. He is also the co-lead of an International Myeloma Foundation support group in Santa Fe, New Mexico and has attended ASH at the invitation of the IMF for three years. He will again be attending ASH 2019 in Orlando, Florida and is interested in the new antibody therapies, the new Chimeric Antigen Receptor (CAR-T) therapies, Chimeric Antigen Receptor-Directed Natural Killer cell (CAR NK) therapy, Bispecific T-cell Engager (BiTEs) therapies and the new drugs such as Iberdomide (CC 220).

The Size of the Dog

John DeFlice |

In the words of Mark Twain, “It’s not the size of the dog in the fight but fight in the dog.” We are often so consumed by our bad feelings that we don’t have the energy to deal with the issues that accompany us on our myeloma journey.  When listening to the speakers at the […]

“Baby, baby, baby what will it be?” —Prince

John DeFlice |

With so many great studies covered at ASH 2019, what will take home the honors for the best outstanding oral presentation? Will it be a Chimeric Antigen Receptor (CAR) or Bispecific T-cell Engager (BiTEs) trials, or will it be a new four-drug combination trial? How about one study that has a 100% response rate in myeloma […]